izpis_h1_title_alt

TRIM28 selective nanobody reduces glioblastoma stem cell invasion
ID Porčnik, Andrej (Author), ID Novak, Metka (Author), ID Breznik, Barbara (Author), ID Majc, Bernarda (Author), ID Hrastar, Barbara (Author), ID Šamec, Neja (Author), ID Zottel, Alja (Author), ID Jovchevska, Ivana (Author), ID Vittori, Miloš (Author), ID Rotter, Ana (Author), ID Komel, Radovan (Author), ID Lah Turnšek, Tamara (Author)

.pdfPDF - Presentation file, Download (1,59 MB)
MD5: 695FE1C98BA264B22AB018FF6CB0DAAF
URLURL - Source URL, Visit https://www.mdpi.com/1420-3049/26/17/5141 This link opens in a new window

Abstract
Glioblastoma (GB), is the most common and aggressive malignant primary brain tumour in adults. Intra- and inter-tumour heterogeneity, infiltrative GB cell invasion and presence of therapy-resistant GB stem cells (GSCs) represent major obstacles to favourable prognosis and poor therapy response. Identifying the biomarkers of the most aggressive tumour cells and their more efficient targeting strategies are; therefore, crucial. Recently, transcription factor TRIM28 has been identified as a GB biomarker and, in this study, we have shown high expression of TRIM28 in GB and in low grade gliomas as well as higher expression in GSCs vs. differentiated GB cells, although in both cases not significant. We demonstrated significant in vitro inhibition of GB cells and GSCs invasiveness and spread in zebrafish brains in vivo by anti-TRIM28 selective nanobody NB237. TRIM28 was also enriched in GB (tumour) core and associated with the expression of stem cell genes, but was not prognostic for overall survival. However, based on the above results, we conclude that TRIM28 nanobody NB237 offers a new opportunity as a GB therapeutic tool.

Language:English
Keywords:glioblastoma, nanobody, glioblastoma stem cells, cell invasion, transcription factor, TRIM28
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:MF - Faculty of Medicine
BF - Biotechnical Faculty
FKKT - Faculty of Chemistry and Chemical Technology
Publication status:Published
Publication version:Version of Record
Year:2021
Number of pages:16 str.
Numbering:Vol. 26, iss. 17, art. 5141
PID:20.500.12556/RUL-135965 This link opens in a new window
UDC:620.3:620.1/.2
ISSN on article:1420-3049
DOI:10.3390/molecules26175141 This link opens in a new window
COBISS.SI-ID:74227715 This link opens in a new window
Publication date in RUL:05.04.2022
Views:4159
Downloads:89
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Molecules
Shortened title:Molecules
Publisher:MDPI
ISSN:1420-3049
COBISS.SI-ID:18462981 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:01.09.2021

Secondary language

Language:Slovenian
Keywords:glioblastom, TRIM28, nanoprotitelesa

Projects

Funder:ARRS - Slovenian Research Agency
Project number:P1-0245
Name:Ekotoksikologija, toksikološka genomika in karcinogeneza

Funder:ARRS - Slovenian Research Agency
Project number:Z3-1870
Name:Vpliv mezenhimskih matičnih celic na odpornost glioblastoma na terapijo

Funder:ARRS - Slovenian Research Agency
Project number:Z3-1869
Name:Razvoj anti-FREM2 nanotelesa in njegova uporaba pri ciljanju glioblastomskih celic

Funder:ARRS - Slovenian Research Agency
Project number:Z3-2649
Name:Določitev novih biomarkerjev glioblastoma za namen neinvazivne tekočinske biopsije

Funder:EC - European Commission
Funding programme:Slovenia-Italy Interreg
Acronym:TRANS-GLIOMA

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back